Objective:To observe the effect of risperidone on psychiatric scale ,nerve function and the quality of life(QOL) in patients with mental disorders caused by craniocerebral injuries .Methods:98 patients with craniocerebral injuries ,including 65 patients with mental disorders ,were randomly divided into the experimental group (33 cases) and the control group (32 cases) ,and other 33 cases as the blank group .All of the patients received clinical routine treatment according to the condition after admission to the hospital .The experimental group used risperidone and the control group used sulpiride treated with mental disorders .All the scores of brief psychiatric racing scale(BPRS) ,activty of daily living(ADL) and National Institutes of Health Stroke scale(HIHSS) before treatment and 2、4、8 weeks after treatment were observed and compared to speculate patients’ neural functional recovery ,treatment effect and QOL . Results:NIHSS and BPRS scores in the experimental group and control group were higher and ADL scores were lower than the blank group before treatment(P<0 .05) .The difference between the experi‐mental group and the control group was not statistically significant(P>0 .05) .All patients’ NIHSS and BPRS scores gradually declined and ADL scores increased after treatment ,significantly different compared with those before treatment(P<0 .05) .NIHSS and BPRS scores in 2 week ,after treatment were not sta‐tistically significant between the experimental group and the control group(P>0 .05) .NIHSS ,and BPRS scores in the experimental group were significantly lower and ADL scores were significantly higher than theose of the control group 4 and 8 weeks after treatment (P<0 .05) .NIHSS ,BPRS and ADL scores in the experimental group were very much closed to the blank group 8 weeks after treatment ,without statis‐tical significance(P>0 .05) .Conclusion:Risperidone has good curative effect upon patients with mental disorders caused by craniocerebral injury .It can promote patients’ nerve functional recovery ,reduce men‐tal score and improve the QOL .%目的：观察利培酮对颅脑损伤所致精神障碍患者精神病量表、神经功能及生存品质（QOL）的影响。方法：98例颅脑损伤患者中65例伴有精神障碍，将其随机分为观察组（33例）及对照组（32例），另外33例不伴精神障碍患者作为空白组。所有患者入院后根据病情行临床常规治疗。其中观察组使用利培酮及对照组使用舒必利对症处理伴发精神障碍。观察对比所有患者治疗前及治疗后第2、4、8周时的神经功能缺损评定量表（NIHSS）评分、简明精神病量表（BPRS）评分及日常生活能力量表（ADL）评分，以判断患者神经功能恢复情况、治疗效果及QOL。结果：观察组与对照组治疗前NIHSS、BPRS评分均高于空白组，ADL评分低于空白组（P＜0．05），而两组间比较差异无统计学意义（P＞0．05）。3组患者经治疗后，NIHSS、BPRS评分均随着时间推移逐渐下降，ADL评分均有所上升，且治疗后第2、4、8周与同组治疗前比较，差异均存在显著意义（P＜0．05）；观察组与对照组比较，治疗后第2周NIHSS、BPRS评分差异无统计学意义（P＞0．05），而治疗后第4、8周观察组NIHSS、BPRS评分明显低于对照组，ADL评分明显高于对照组（P＜0．05）；且治疗后第8周，观察组的NIHSS、BPRS、ADL评分几乎接近空白组，差异无统计学意义（P＞0．05）。结论：利培酮对颅脑损伤所致精神障碍患者具有良好疗效，能促进患者神经功能的恢复，降低精神病评分，改善患者的QOL。
展开▼
